Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102384374 | 10238437 | 4 | F | 20150625 | 20140616 | 20150630 | EXP | PHHY2014CA073310 | NOVARTIS | 0.00 | M | Y | 0.00000 | 20150630 | N | CN | COUNTRY NOT SPECIFIED | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102384374 | 10238437 | 1 | PS | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | 30 MG, EVERY 4 WEEKS | D | 21008 | 30 | MG | SUSPENSION | /month |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 102384374 | 10238437 | 1 | Acral overgrowth |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 102384374 | 10238437 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 102384374 | 10238437 | Blindness unilateral | |
| 102384374 | 10238437 | Cardiac disorder | |
| 102384374 | 10238437 | Depression | |
| 102384374 | 10238437 | Eye disorder | |
| 102384374 | 10238437 | Eye swelling | |
| 102384374 | 10238437 | Gait disturbance | |
| 102384374 | 10238437 | Hypoaesthesia | |
| 102384374 | 10238437 | Limb discomfort | |
| 102384374 | 10238437 | Mental disorder | |
| 102384374 | 10238437 | Peripheral swelling |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |